{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T17:27:21Z","timestamp":1786728441975,"version":"build-2736575974"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>\n                    A\n                    <jats:sc>BSTRACT<\/jats:sc>\n                  <\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Information on the plasma ranges of prescribed voriconazole prophylactic and therapeutic drug levels among the patients with invasive fungal infections (IFIs) is sparsely documented from central India.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This prospective observational database study was conducted over a period of 18 months at the ICMR Mycology Advanced Resource Center of a tertiary care hospital in central India. It included 25 voriconazole samples from 18 patients undergoing routine therapeutic drug monitoring (TDM). Clinico-mycological characteristics, target concentration ranges for prophylactic and therapeutic prescriptions, and clinical outcomes were evaluated among enrolled patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Out of the 25 samples, 8 (32%) were random and 17 (68%) were trough samples. 33.3% (6\/18) had repeat samples sent for analysis. Out of the 18 patients enrolled, 10 (55%) received prophylactic, while 8 (44%) were received therapeutic doses of voriconazole. Overall mean concentration of voriconazole in trough samples was 3.93 \u03bcg\/ml, and in random samples was 2.38 \u03bcg\/ml. Both these values were within the normal range. Commonest drug-drug interaction (DDI), between proton pump inhibitor (PPI) use and voriconazole was evident in supratherapeutic voriconazole concentrations. With small sample size, exploratory nature of this study and without a multivariable analysis; the association of PPIs alone for supratherapeutic voriconazole concentrations cannot be established.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The research highlighted notable pharmacokinetic variances between children and adults who received voriconazole, particularly concerning the rate of absorption, bioavailability, and metabolism. This study emphasizes the need for antifungal TDM in developing nations with resource limited settings in better understanding of IFI management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jpbs.jpbs_1699_25","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T18:00:20Z","timestamp":1778781620000},"page":"160-168","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Experience of a Single-Center Voriconazole TDM Bioassay for Hospitalized Patients with Invasive Fungal Infections"],"prefix":"10.4103","volume":"18","author":[{"given":"Sevitha","family":"Venkatesan","sequence":"first","affiliation":[{"name":"Department of Microbiology, ICMR Mycology Advanced Resource Center, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arati","family":"Bhadade","sequence":"additional","affiliation":[{"name":"Department of Microbiology, ICMR Mycology Advanced Resource Center, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhu","family":"Panthi","sequence":"additional","affiliation":[{"name":"Department of Microbiology, ICMR Mycology Advanced Resource Center, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Saigal","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Critical Care, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Khadanga","sequence":"additional","affiliation":[{"name":"Department of General Medicine, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Bansal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Haematology, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand Kumar","family":"Maurya","sequence":"additional","affiliation":[{"name":"Department of Microbiology, ICMR Mycology Advanced Resource Center, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Division of Infectious Diseases, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gajendra","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Microbiology, ICMR Mycology Advanced Resource Center, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepti","family":"Joshi","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Goyal","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Graphic Era Institute of Medical Sciences, Dehradun, Uttarakhand, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alkesh","family":"Khurana","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep","family":"Saxena","sequence":"additional","affiliation":[{"name":"Department of General Surgery, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikha","family":"Malik","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radha Sarawagi","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Radidiagnosis, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Upadhyay","sequence":"additional","affiliation":[{"name":"Department of Microbiology, ICMR Mycology Advanced Resource Center, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anju","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Microbiology, ICMR Mycology Advanced Resource Center, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadepalli","family":"Karuna","sequence":"additional","affiliation":[{"name":"Department of Microbiology, ICMR Mycology Advanced Resource Center, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"R1-20260713","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3410\/M3-14","article-title":"Emerging fungal infections in immunocompromised patients","volume":"3","author":"Low","year":"2011","journal-title":"F1000 Med Rep"},{"key":"R2-20260713","doi-asserted-by":"crossref","first-page":"e200430","DOI":"10.1590\/0074-02760200430","article-title":"Invasive fungal disease in humans: Are we aware of the real impact?","volume":"115","author":"Firacative","year":"2020","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"R3-20260713","doi-asserted-by":"crossref","first-page":"507","DOI":"10.7861\/clinmedicine.13-5-507","article-title":"Invasive fungal infections","volume":"13","author":"Hope","year":"2013","journal-title":"Clin Med (Lond)"},{"key":"R4-20260713","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: Guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"R5-20260713","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R6-20260713","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12281-016-0255-4","article-title":"Therapeutic drug monitoring of posaconazole: An update","volume":"10","author":"Dekkers","year":"2016","journal-title":"Curr Fungal Infect Rep"},{"key":"R7-20260713","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/phar.1631","article-title":"Pharmacokinetic and pharmacodynamic properties of oral voriconazole in patients with invasive fungal infections","volume":"35","author":"Wang","year":"2015","journal-title":"Pharmacotherapy"},{"key":"R8-20260713","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1185\/03007995.2012.761135","article-title":"Optimizing antifungal choice and administration","volume":"29","author":"Andes","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"R9-20260713","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/myc.12339","article-title":"Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: Single centre retrospective analysis","volume":"58","author":"Miceli","year":"2015","journal-title":"Mycoses"},{"key":"R10-20260713","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/FTD.0000000000000235","article-title":"Subtherapeutic posaconazole exposure and treatment outcome in patients with invasive fungal disease","volume":"37","author":"van der Elst","year":"2015","journal-title":"Ther Drug Monit"},{"key":"R11-20260713","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.eimc.2014.09.005","article-title":"Clinical usefulness of therapeutic drug monitoring of voriconazole in a university hospital","volume":"33","author":"Cabral-Galeano","year":"2015","journal-title":"Enferm Infecc Microbiol Cl\u00edn"},{"key":"R12-20260713","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R13-20260713","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/jac\/dkw099","article-title":"Utility of voriconazole therapeutic drug monitoring: A meta-analysis","volume":"71","author":"Luong","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"R14-20260713","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/myc.12948","article-title":"Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations","volume":"62","author":"M\u00e4rtson","year":"2019","journal-title":"Mycoses"},{"key":"R15-20260713","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-6143.2010.03375.x","article-title":"Antifungal prophylaxis in lung transplantation\u2014a world-wide survey","volume":"11","author":"Neoh","year":"2011","journal-title":"Am J Transplant"},{"key":"R16-20260713","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1128\/AAC.01558-13","article-title":"A reference laboratory experience of clinically achievable voriconazole, posaconazole, and itraconazole concentrations within the bloodstream and cerebral spinal fluid","volume":"58","author":"Wiederhold","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"R17-20260713","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/jac\/dkm389","article-title":"Antifungal serum concentration monitoring: An update","volume":"61","author":"Goodwin","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"R18-20260713","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1128\/AAC.01053-05","article-title":"Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: Fluconazole and Candida albicans","volume":"50","author":"Andes","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R19-20260713","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/imj.12600","article-title":"Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014","volume":"44","author":"Chau","year":"2014","journal-title":"Intern Med J"},{"key":"R20-20260713","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s12281-022-00430-4","article-title":"Azole therapeutic drug monitoring and its use in the management of invasive fungal disease","volume":"16","author":"Ashok","year":"2022","journal-title":"Curr Fungal Infect Rep"},{"key":"R21-20260713","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/bcpt.13465","article-title":"Voriconazole therapeutic drug monitoring in critically ill patients improves efficacy and safety of antifungal therapy","volume":"127","author":"Li","year":"2020","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R22-20260713","first-page":"31","article-title":"Genetic polymorphism of cytochrome P450 enzymes in Asian populations: Focus on CYP2D6","volume":"23","author":"Kitada","year":"2003","journal-title":"Int J Clin Pharmacol Res"},{"key":"R23-20260713","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","article-title":"Pharmacokinetic\/pharmacodynamic profile of voriconazole","volume":"45","author":"Theuretzbacher","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"R24-20260713","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S1470-2045(10)70114-5","article-title":"Glucocorticoid use in acute lymphoblastic leukemia: Comparison of prednisone and dexamethasone","volume":"11","author":"Inaba","year":"2010","journal-title":"Lancet Oncol"},{"key":"R25-20260713","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol Ther"},{"key":"R26-20260713","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/jcpt.12401","article-title":"Subtherapeutic voriconazole concentrations associated with concomitant dexamethasone: Case report and review of the literature","volume":"41","author":"Wallace","year":"2016","journal-title":"J Clin Pharm Ther"},{"key":"R27-20260713","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1124\/mol.64.2.316","article-title":"Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter","volume":"64","author":"Chen","year":"2003","journal-title":"Mol Pharmacol"},{"key":"R28-20260713","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1128\/AAC.00626-12","article-title":"Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"R29-20260713","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1046\/j.1365-2125.2003.01997.x","article-title":"Coadministration of voriconazole and phenytoin: Pharmacokinetic interaction, safety, and toleration","volume":"56","author":"Purkins","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"R30-20260713","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1365-2125.2008.03315.x","article-title":"High voriconazole trough levels in relation to hepatic function: How to adjust the dosage?","volume":"67","author":"Alffenaar","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"R31-20260713","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1093\/cid\/cix443","article-title":"Substantial impairment of voriconazole clearance by high-dose meropenem in a patient with renal failure","volume":"65","author":"Mahmoudi","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R32-20260713","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3947\/ic.2011.43.5.421","article-title":"A case of visual and auditory hallucinations during intravenous voriconazole therapy","volume":"43","author":"Kim","year":"2011","journal-title":"Infect Chemother"},{"key":"R33-20260713","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1111\/bcp.14578","article-title":"Population pharmacokinetics, safety and dosing optimization of voriconazole in patients with liver dysfunction: A prospective observational study","volume":"87","author":"Tang","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"R34-20260713","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1128\/AAC.04993-14","article-title":"Population pharmacokinetic analysis of voriconazole from a pharmacokinetic study with immunocompromised Japanese pediatric subjects","volume":"59","author":"Muto","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R35-20260713","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/jac\/dku031","article-title":"Understanding variability with voriconazole using a population pharmacokinetic approach: Implications for optimal dosing","volume":"69","author":"Dolton","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"R36-20260713","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1086\/648679","article-title":"Voriconazole pharmacokinetics and pharmacodynamics in children","volume":"50","author":"Neely","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R37-20260713","doi-asserted-by":"crossref","first-page":"204209862211275","DOI":"10.1177\/20420986221127503","article-title":"Therapeutic drug monitoring and safety evaluation of voriconazole in the treatment of pulmonary fungal diseases","volume":"13","author":"Shen","year":"2022","journal-title":"Ther Adv Drug Saf"},{"key":"R38-20260713","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4103\/jpbs.jpbs_934_25","article-title":"A Prospective observational study in adult medical Intensive Care Unit patients with drug-induced QTc with correlation of serum potassium, magnesium level of clinical outcome","volume":"17","author":"Menaka","year":"2025","journal-title":"J Pharm Bioallied Sci"}],"container-title":["Journal of Pharmacy and Bioallied Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jpbs.jpbs_1699_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:27:04Z","timestamp":1786724824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jpbs.jpbs_1699_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/jpbs.jpbs_1699_25","relation":{},"ISSN":["0976-4879","0975-7406"],"issn-type":[{"value":"0976-4879","type":"print"},{"value":"0975-7406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"2025-10-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}